An RNA-altering startup, led by some of the brains behind Biogen and Sarepta Therapeutics’ blockbuster products, is hoping to raise $86 million in an IPO, the company disclosed Thursday.

Stoke Therapeutics Inc. is developing RNA-targeting treatments that it hopes can jumpstart protein production in a handful of genetic diseases like a rare form of epilepsy called Dravet’s Syndrome. It is also exploring potential therapies for liver, central nervous system, eye and kidney diseases.

The preclinical…

Boston Biz Journal